Nautilus Biotechnology Inc’s recent filing unveils that its CEO, President, and Secretary Patel Sujal M acquired Company’s shares for reported $78544.0 on Sep 05 ’25. In the deal valued at $0.67 per share,116,500 shares were bought. As a result of this transaction, Patel Sujal M now holds 10,258,221 shares worth roughly $6.98 million.
Then, Patel Sujal M bought 83,500 shares, generating $57,031 in total proceeds. Upon buying the shares at $0.68, the CEO, President, and Secretary now owns 10,341,721 shares.
Before that, Murphy Matthew B. bought 20,000 shares. Nautilus Biotechnology Inc shares valued at $12,858 were divested by the General Counsel at a price of $0.64 per share. As a result of the transaction, Murphy Matthew B. now holds 74,140 shares, worth roughly $50415.200000000004.
Goldman downgraded its Nautilus Biotechnology Inc [NAUT] rating to a Sell from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Morgan Stanley started covering the stock on January 06, 2022. It rated NAUT as “an Equal-weight”.
Price Performance Review of NAUT
On Friday, Nautilus Biotechnology Inc [NASDAQ:NAUT] saw its stock fall -6.57% to $0.68. Over the last five days, the stock has lost -5.51%. Nautilus Biotechnology Inc shares have fallen nearly -76.56% since the year began. Nevertheless, the stocks have fallen -59.46% over the past one year.
How much short interest is there in Nautilus Biotechnology Inc?
A steep rise in short interest was recorded in Nautilus Biotechnology Inc stocks on 2025-08-29, dropping by 42843.0 shares to a total of 0.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 0.27 million shares. There was a decline of -19.01%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 02, 2021 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating.
